Clinical Trial Update: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 study results report on the long-term safety and tolerability of faricimab in neovascular age-related macular degeneration, with results posted after co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2025-10-24